To ascertain if the in vitro role of PRL-3 correlated with FLT3-ITD-driven AML tumour burden in vivo, we developed a leukaemia mouse model using the lateral tail vein injection of AML cells. This evidence concerns the gene FLT3 and acute myeloid leukemia.